argenx: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 2 days ago
714 argenex SE $ARGX Shares Bought by Diversify Advisory Services LLCDefense World · 2 days ago
argenx SE (ARGX) Q3 2026 Earnings Call TranscriptSeeking Alpha · 2 days ago
HRMY or ARGX: Which Is the Better Value Stock Right Now?Zacks Investment Research · 2 days ago
What argenex (ARGX) Said on Its Q3 Earnings CallMarketBeat · 2 days ago
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026GlobeNewsWire · Oct 15, 2026argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $7.44 | $7.80 | Beat |
| May 7, 2026 | $5.16 | $5.90 | Beat |
| Oct 30, 2025 | $4.37 | $5.18 | Beat |
| May 8, 2025 | $2.32 | $2.58 | Beat |
| Oct 31, 2024 | $0.10 | $1.39 | Beat |
| May 9, 2024 | -$0.71 | -$1.04 | Miss |